Senseonics (NYSE:SENS) this week said it launched its Eversense continuous glucose monitoring system with its mobile app that can dose based on the system’s readings.
The Eversense System is a long-term, implantable CGM sensor that features a transmitter that sends discreet vibrations to alert users of low and high glucose levels. The system with the CGM mobile app can dose insulin based on system readings without the need for a confirmatory blood glucose finger stick measurement.
Get the full story on our sister site, Drug Delivery Business News.